Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Bergman
Arthur J
AJ
Merck Research Laboratories, P.O. Box 4, WP75B-100, West Point, PA 19486, USA. arthur_bergman@merck.com
Cote
Josee
J
Yi
Bingming
B
Marbury
Thomas
T
Swan
Suzanne K
SK
Smith
William
W
Gottesdiener
Keith
K
Wagner
John
J
Herman
Gary A
GA
D000293:Adolescent; D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000493:pharmacokinetics*; D051437:Renal Insufficiency / Q000209:etiology / Q000503:physiopathology*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000493:pharmacokinetics*
D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate